Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension. - Moon JS; Han KA; Yu JM; Won JC; Kang JG; Park S; Park CY (Diabetes research and clinical practice, 2026)